Recombinant epidermal growth factor - Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals

Drug Profile

Recombinant epidermal growth factor - Center for Genetic Engineering and Biotechnology/Praxis Pharmaceuticals

Alternative Names: Heberprot-P; Heberprot-P 75; hrecEGF; rhEGF; rhuEGF

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology; Praxis Pharmaceuticals
  • Class Antiulcers; Growth factors
  • Mechanism of Action Epidermal growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Diabetic foot ulcer

Most Recent Events

  • 11 Aug 2013 Registered for Diabetic foot ulcer in Angola (Intralesional)
  • 31 Jan 2013 Phase-II clinical trials in Diabetic foot ulcer in Spain (Intralesional)
  • 31 Jan 2013 Heberprot-P is available for licensing in selected territories as of 31 Jan 2013. www.icgeb.org/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top